MedPath

MBRS-Based Psychoeducation in Patients With Schizophrenia

Not Applicable
Completed
Conditions
Mindfulness Training
Registration Number
NCT07130227
Lead Sponsor
Ataturk University
Brief Summary

This study aimed to determine the effects of mindfulness-based stress reduction training on anger management and functional recovery in patients with schizophrenia. The study will be conducted at a CMHC in Ağrı province between May and August 2021. At the CMHC, community-based mental health services are provided to patients with severe mental disorders (schizophrenia, bipolar disorder) who are in remission as assessed by a psychiatrist. The study is planned to be conducted with patients who meet the study criteria, without using a sample selection method. Patients over the age of 18 registered with CMHC and followed with a diagnosis of schizophrenia were contacted by phone and invited to CMHC. The study was conducted with patients who met the inclusion criteria and agreed to participate (psychoeducational group, mindfulness group, control group). Data will be collected using the Descriptive Characteristics Form, the State and Trait Anger Inventory, and the SILO. The mindfulness group received 16 sessions of MBRS training, and the psychoeducational group received an 8-session psychoeducational program. The control group received no intervention. The study sample size was calculated using the GPower computer program. Power analysis at α=0.05 yielded an effect size of 150, 153 (d=0.8), and the study had 90% power. Therefore, it was calculated that a minimum of 68 patients should be included in the sample.

Detailed Description

Study data were collected by the researcher through face-to-face interviews. The study included individuals diagnosed with schizophrenia who met the inclusion criteria (registration in a CMHC, having a diagnosis of schizophrenia, willingness to participate in the study, and openness to communication and collaboration). Pre-test measurement instruments were administered to the participants. The mindfulness group then received 16 sessions of MBRS training, and the psychoeducation group received an 8-session psychoeducation program. The control group received no intervention. Post-test data were collected following the training sessions.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Being registered with a CMHC
  • Being diagnosed with schizophrenia
  • Being between the ages of 18 and 60
  • Being willing to participate in the study
  • Being open to communication and cooperation
  • Being in remission
Exclusion Criteria
  • Not being open to communication and cooperation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Personal Information Formup to 1 day

This form consists of a total of eight questions (age, gender, marital status, education level, duration of illness, income, family history of mental illness, and employment status) developed by the researcher based on literature and includes the sociodemographic characteristics of the patients

Secondary Outcome Measures
NameTimeMethod
The State-Trait Anger Scale (STAS)up to 1 day

This is a self-report scale measuring the feeling and expression of anger. It was developed by Spielberger et al., and its Turkish validity and reliability study was conducted by Özer. The Cronbach's alpha obtained in this study was 0.84. The scale is a four-point Likert-type scale consisting of four subscales: anger-in, anger-out, anger control, and trait anger, and 34 items. High scores on the trait anger dimension indicate high anger levels, high scores on the anger control dimension indicate that anger can be controlled, high scores on the anger-out dimension indicate that anger is easily expressed, and high scores on the anger-in dimension indicate that anger is suppressed.

Trial Locations

Locations (1)

Ataturk University Faculty of Nursing

🇹🇷

Erzurum, Yakutiye, Turkey

Ataturk University Faculty of Nursing
🇹🇷Erzurum, Yakutiye, Turkey

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.